Shawn Baldacchino

Dr. Shawn Baldacchino

Mater Dei Hospital, Imsida, Malta
orcid

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 November 2018 in Journal of Extracellular Vesicles
Verified
Journal Article
Open access
CTClotilde Théry
Clotilde Théry
KWKenneth Witwer
Kenneth Witwer
EAElena Aikawa
Elena Aikawa
MAMaria Jose Alcaraz
Maria Jose Alcaraz
JAJohnathon Anderson
Johnathon Anderson
Ewa Zuba-SurmaEwa Zuba-Surma
Ewa Zuba-Surma
The last decade has seen a sharp increase in the number of scientific publications describing physiological and pathological functions of extracellular vesicles (EVs), a collective term covering various subtypes of cell‐released, membranous structures, called exosomes, microvesicles, microparticles, ectosomes, oncosomes, apoptotic bodies, and many other names. However, specific issues arise when working with these entities, whose size and amount often make them difficult to obtain as relatively pure preparations, and to characterize properly. The International Society for Extracellular Vesicles (ISEV) proposed Minimal Information for Studies of Extracellular Vesicles (“MISEV”) guidelines for the field in 2014. We now update these “MISEV2014” guidelines based on evolution of the collective knowledge in the last four years. An important point to consider is that ascribing a specific function to EVs in general, or to subtypes of EVs, requires reporting of specific information beyond mere description of function in a crude, potentially contaminated, and heterogeneous preparation. For example, claims that exosomes are endowed with exquisite and specific activities remain difficult to support experimentally, given our still limited knowledge of their specific molecular machineries of biogenesis and release, as compared with other biophysically similar EVs. The MISEV2018 guidelines include tables and outlines of suggested protocols and steps to follow to document specific EV‐associated functional activities. Finally, a checklist is provided with summaries of key points.

7 March 2017 in Oncotarget
Verified
Journal Article
Open access
PDF file
RDRosa Drago-Ferrante
Rosa Drago-Ferrante
Francesca PentimalliFrancesca Pentimalli
Francesca Pentimalli
DCDaniela Carlisi
Daniela Carlisi
ABAnna De Blasio
Anna De Blasio
CSChristian Saliba
Christian Saliba
RICCARDO DI FIORERICCARDO DI FIORE
RICCARDO DI FIORE
Suppressive role exerted by microRNA-29b-1-5p in triple negative breast cancer through SPIN1 regulation Suppressive role exerted by microRNA-29b-1-5p in triple negative breast cancer through SPIN1 regulation

21 July 2016 in Tumor Biology
Verified
Journal Article
Closed access
PDF file
GGGodfrey Grech
Godfrey Grech
SBShawn Baldacchino
Shawn Baldacchino
CSChristian Saliba
Christian Saliba
MGMaria Pia Grixti
Maria Pia Grixti
RGRobert Gauci
Robert Gauci
CSChristian Scerri
Christian Scerri

25 January 2014 in EPMA Journal
Verified
Journal Article
Open access
PDF file
SBShawn Baldacchino
Shawn Baldacchino
CSChristian Saliba
Christian Saliba
VPVanessa Petroni
Vanessa Petroni
AFAnthony G Fenech
Anthony G Fenech
NBNigel Borg
Nigel Borg
GGGodfrey Grech
Godfrey Grech
Background: The most commonly used biomarkers to predict the response of breast cancer patients to therapy are the oestrogen receptor (ER), progesterone receptor (PgR), and human epidermal growth factor receptor 2 (HER2). Patients positive for these biomarkers are eligible for specific therapies such as endocrine treatment in the event of ER and PgR positivity, and the monoclonal antibody, trastuzumab, in the case of HER2-positive patients. Patients who are negative for these three biomarkers, the so-called triple negatives, however, derive little benefit from such therapies and are associated with a worse prognosis. Deregulation of the protein serine/threonine phosphatase type 2A (PP2A) and its regulatory subunits is a common event in breast cancer, providing a possible target for therapy. Methods: The data portal, cBioPortal for Cancer Genomics was used to investigate the incidence of conditions that are associated with low phosphatase activity. Four (4) adherent human breast cancer cell lines, MDA-MB-468, MDA-MB-436, Hs578T and BT-20 were cultured to assess their viability when exposed to various dosages of rapamycin or FTY720. In addition, RNA was extracted and cDNA was synthesised to amplify the coding sequence of PPP2CA. Amplification was followed by high-resolution melting to identify variations. Results and conclusion: The sequence of PPP2CA was found to be conserved across a diverse panel of solid tumour and haematological cell lines, suggesting that low expression of PPP2CA and differential binding of inhibitory PPP2CA regulators are the main mechanisms of PP2A deregulation. Interestingly, the cBioPortal for Cancer Genomics shows that PP2A is deregulated in 59.6% of basal breast tumours. Viability assays performed to determine the sensitivity of a panel of breast cancer cell lines to FTY720, a PP2A activator, indicated that cell lines associated with ER loss are sensitive to lower doses of FTY720. The subset of patients with suppressed PP2A activity is potentially eligible for treatment using therapies which target the PI3K/AKT/mTOR pathway, such as phosphatase activators.

1 February 2020 in Seminars in Cancer Biology
Verified
Journal Article
Closed access
SBShawn Baldacchino
Shawn Baldacchino
GGGodfrey Grech
Godfrey Grech

25 March 2019 in Journal of Cellular Physiology
Verified
Journal Article
Closed access
PDF file
ABAnna De Blasio
Anna De Blasio
GPGiovanni Pratelli
Giovanni Pratelli
RDRosa Drago‐Ferrante
Rosa Drago‐Ferrante
CSChristian Saliba
Christian Saliba
SBShawn Baldacchino
Shawn Baldacchino
RICCARDO DI FIORERICCARDO DI FIORE
RICCARDO DI FIORE